Mr. Taub has served as a member of the Board of Directors since July 2007 and chairman of its board of directors since November 2013. He founded and filled the role of CEO and a member of the board of directors of Omrix Biopharmaceuticals Inc., a biopharmaceutical company that developed, manufactured, and marketed biological products for the biosurgical and immunotherapy markets. The company was acquired by Johnson & Johnson in 2008. Mr. Taub is Chairman of Nyxoah S.A., which develops implants to treat sleep apnea, and director of LifeBond, Ltd., a company that develops surgical sealants.
Mr. Taub holds a BA in Languages from RUCA Antwerp University and an MBA from INSEAD (Fontainebleau).
Dr. Cabilly has served as a member of the Board of Directors since September 2009. Dr. Cabilly is a scientist and inventor in the field of immunology. He holds two landmark patents related to artificial synthesis of antibody molecules that led to the development of several commercial drugs by major biotech companies. He was co-founder Chief Scientist of Ethrog Biotechnologies Ltd., where he invented dry buffer technologies enabling the production of a disposable apparatus for gel electrophoresis containing no liquid, as well as a technology for molecular separation within small zones. In 2001, Ethrog Biotechnologies Ltd. was acquired by Invitrogen Corp. (Thermo Fisher Scientific Inc.). Dr. Cabilly serves as a director for several bio-tech companies.
Dr. Cabilly holds a BSc in Biology from the Ben-Gurion University of the Negev, and an MSc and a PhD in Immunology and Microbiology from the Hebrew University of Jerusalem.
Mr. Wascher has served as a member of the Board of Directors since July 2007. In 2000, Mr. Wascher founded Wascher and Partner, a company that specializes in mergers and acquisitions consultancy and providing start-up advice in the fields of specialty chemicals and plastics. From 1984 to 2000, he served as a vice president of General Electric. Currently, Mr. Wascher serves as a non-executive director of Polymer Logistics N.V., Polyscope Polymers B.V. and Nyxoah S.A.
Mr. Wascher holds an MSc in Polymer Science from the Massachusetts Institute of Technology.
Mr. Ellberger has served as a member of the Board of Directors since March 2014. He is Chairman of the Board of Celldex Therapeutics, Inc. and is a Founder and Principal of Healthcare Ventures Associates, Inc., a consulting firm for the pharmaceutical, biotechnology and medical device industries. He was most recently Interim CEO of PDI, Inc., a diversified sales and marketing services provider to the biopharmaceutical, medical device and diagnostic industries. From 2000 to 2003, he was Senior Vice President of Powderject plc, where he also served as a director. Mr. Ellberger is currently on the board of directors of Transpharma, Ltd. and The Jewish Children’s Museum and was Chairman of the board of Omrix Biopharmaceuticals Ltd. until its acquisition by Johnson & Johnson in 2008.
Mr. Ellberger holds a BA in Economics from Columbia College and a BSc in Chemical Engineering from Columbia School of Engineering.
Ms. Felder serves as our external director of the board of directors since November 2014. Ms. Felder also serves as a director for Carmit Candy Industries Ltd., a TASE listed company since October 2014. Additionally, since 2010, Ms. Felder has served as the external CFO for two technology companies, while also serving on the board of directors of the following NASDAQ and/or TASE listed companies: Enlight Renewable Energy Ltd. (Eurocom group); Crow Technologies 1977 Ltd.; Argaman Industries Ltd.; Zmiha Ltd.; and Profit Industries Ltd. Ms. Felder has also served on the board of directors of several private companies during that same period of time. Since 2003, Ms. Felder has been a lecturer at the College of Management Academic Studies Division, Rishon Lezion, Israel. From 1997 to 2010, she worked for PriceWaterhouseCoopers as a Senior Manager. Ms. Felder received a degree in Business Administration and accounting from the College of Management Academic Studies Division in Rishon Lezion, Israel and an Executive Master’s degree in the Science of Finance from the City University of New York.
Mr. Kalman serves as our external director of the board of directors since November 2014. Since 2005, Mr. Kalman has served as a director and the Chief Executive Officer of Dion Investments Ltd., a privately held investment company, which Mr. Kalman founded in 1999. Dion Investments invests in early stage technology companies and prime real estate. He is also currently on the board of directors of The Jerusalem Print Workshop, a non-profit art center dedicated to the advancement of the graphic arts in Israel.
Oded S. Lieberman
Dr. Lieberman has 25 years international experience in corporate leadership, technology development and the successful launch and commercialization of diagnostics, drugs and medical devices. He has served as CEO of NeuroDerm since December 2007 and was Chairman of the Board between 2005 and 2013. He previously held the positions of CEO and President of Proteologics Ltd., and Vice President of Surgical Products at Omrix Biopharmaceuticals Ltd. (later floated on NASDAQ (OMRX) and acquired by J&J). Prior to Omrix, Oded held senior management positions at Octapharma AG and Boehringer Mannheim GmbH (later Roche Diagnostics) including marketing and business development positions and, in addition, served as chairman and/or a member of the board of several health care companies.
Dr. Lieberman has a PhD in Biology from the Hebrew University of Jerusalem and an MBA from INSEAD (Fontainebleau).